Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 401

Similar articles for PubMed (Select 22244023)

1.

Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.

Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, Leucht S, Davis JM.

J Clin Psychiatry. 2011 Dec;72(12):1616-27. doi: 10.4088/JCP.11r06927.

PMID:
22244023
2.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
3.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
4.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

PMID:
14994733
5.

[Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].

Carpiniello B, Mellino G, Pintore S, Puddu L, Pinna F.

Clin Ter. 2011;162(4):331-41. Italian.

PMID:
21912821
6.

Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.

Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T.

J Clin Psychiatry. 2008 Dec;69(12):1901-15. Epub 2008 Sep 9.

PMID:
19012820
7.

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.

Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J.

BMC Psychiatry. 2006 Feb 21;6:8.

8.

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2006 Apr;163(4):611-22.

PMID:
16585435
9.

Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.

Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW.

Arch Gen Psychiatry. 2005 Dec;62(12):1305-12.

PMID:
16330718
10.

All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis.

Beasley CM Jr, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM.

J Clin Psychopharmacol. 2007 Jun;27(3):252-8.

PMID:
17502771
11.

Selection of atypical antipsychotics for the management of schizophrenia.

Sprague DA, Loewen PS, Raymond CB.

Ann Pharmacother. 2004 Feb;38(2):313-9. Epub 2003 Dec 30. Review.

PMID:
14742771
12.

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.

Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group.

Am J Psychiatry. 2003 Aug;160(8):1396-404.

PMID:
12900300
13.

The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

Naber D, Lambert M.

CNS Drugs. 2009 Aug;23(8):649-59. doi: 10.2165/00023210-200923080-00002.

PMID:
19594194
14.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.

N Engl J Med. 2005 Sep 22;353(12):1209-23. Epub 2005 Sep 19. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3.

15.

Aripiprazole in schizophrenia and schizoaffective disorder: A review.

Stip E, Tourjman V.

Clin Ther. 2010;32 Suppl 1:S3-20. doi: 10.1016/j.clinthera.2010.01.021. Review.

PMID:
20152550
16.

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2006 Apr;163(4):600-10.

PMID:
16585434
17.

Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

Houthoofd SA, Morrens M, Sabbe BG.

Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Review.

PMID:
18840365
18.
19.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
20.

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2002 Feb;159(2):255-62. Erratum in: Am J Psychiatry 2002 Dec;159(12):2132.

PMID:
11823268
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk